MiR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 1, 2014, Pages 291-296

  Mathew, Lijoy K ^a,b   Skuli, Nicolas ^a,b   Mucaj, Vera ^a   Lee, Samuel S ^a,b   Zinn, Pascal O ^b   Sathyan, Pratheesh ^b   Imtiyaz, Hongxia Z ^a   Zhang, Zhongfa ^b   Davuluri, Ramana V ^b   Rao, Shilpa ^b   Venneti, Sriram ^b   Lal, Priti ^b   Lathia, Justin D ^c   Rich, Jeremy N ^d   Keith, Brian ^a,d   Minn, Andy J ^e   Simon, M Celeste ^a,b,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; MICRORNA; MICRORNA 218; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MESENCHYMOMA; ONCOGENE C JUN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MESODERM; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84891930533     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314341111     Document Type: Article

References (44)

1. Simon MC, Keith B (2008) The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9(4): 285-296.
2. Stupp R, et al. (2009) Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: A multicentre phase II trial. Lancet Oncol 10(8): 785-793.
3. Brat DJ, et al. (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64(3): 920-927.
4. Cooper LA, et al. (2012) The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 180(5): 2108-2119.
5. Phillips HS, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3): 157-173.
6. Verhaak RG, et al.; Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1): 98-110.
7. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6(4): 259-269.
8. Stahlhut Espinosa CE, Slack FJ (2006) The role of microRNAs in cancer. Yale J Biol Med 79(3-4): 131-140.
9. Silber J, et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14.
10. Godlewski J, et al. (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68(22): 9125-9130.
11. Kulshreshtha R, et al. (2007) A microRNA signature of hypoxia. Mol Cell Biol 27(5): 1859-1867.
12. Davidson MR, et al. (2010) MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS ONE 5(9):e12560.
13. Tie J, et al. (2010) MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6(3):e1000879.
14. Dickinson RE, et al. (2004) Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer 91(12): 2071-2078.
15. Dallol A, et al. (2003) Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene 22(29): 4611-4616.
16. Freije WA, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64(18): 6503-6510.
17. Vital AL, et al. (2010) Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro-oncol 12(9): 991-1003.
18. Huse JT, Phillips HS, Brennan CW (2011) Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia 59(8): 1190-1199.
19. Tso CL, et al. (2006) Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 4(9): 607-619.
20. Alajez NM, et al. (2011) MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 71(6): 2381-2391.
21. Xia H, et al. (2013) MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity. Neuro-oncol 15(4): 413-422.
22. Eyler CE, et al. (2011) Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 146(1): 53-66.
23. Gdynia G, et al. (2010) Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria. Cancer Res 70(21): 8558-8568.
24. Ito N, et al. (2007) Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 81(1): 75-83.
25. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894): 191-195.
26. Thorburn J, et al. (2009) Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 16(1): 175-183.
27. Hegi ME, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10): 997-1003.
28. Oliva CR, et al. (2010) Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem 285(51): 39759-39767.
29. Bhat KP, et al. (2013) Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24(3): 331-346.
30. Nogami M, et al. (2003) Requirement of autophosphorylated tyrosine 992 of EGF receptor and its docking protein phospholipase C gamma 1 for membrane ruffle formation. FEBS Lett 536(1-3): 71-76.
31. Krag C, Malmberg EK, Salcini AE (2010) PI3KC2α, a class II PI3K, is required for dynamin-independent internalization pathways. J Cell Sci 123(Pt 24): 4240-4250.
32. Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A (2008) Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 8:163.
33. Rebocho AP, Marais R (2013) ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. Oncogene 32(26): 3207-3212.
34. Chou CW, et al. (2012) Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neurooncol 14(10): 1227-1238.
35. Kolenda J, et al. (2011) Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 103(1): 43-58.
36. Li Z, et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6): 501-513.
37. Lu Y, Liang K, Li X, Fan Z (2007) Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer 6:63.
38. Xu L, et al. (2010) Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18): 2616-2627.
39. Zhong H, et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60(6): 1541-1545.
40. Meng Q, Xia Y (2011) c-Jun, at the crossroad of the signaling network. Protein Cell 2(11): 889-898.
41. Krock BL, Skuli N, Simon MC (2011) Hypoxia-induced angiogenesis: Good and evil. Genes Cancer 2(12): 1117-1133.
42. Skuli N, et al. (2009) Endothelial deletion of hypoxia-inducible factor-2alpha (HIF- 2alpha) alters vascular function and tumor angiogenesis. Blood 114(2): 469-477.
43. Skuli N, et al. (2012) Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J Clin Invest 122(4): 1427-1443.
44. Cheng L, et al. (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153(1): 139-152.